Skip to main content
OpenTrials
Completed

NCT Number: NCT00878631

Feasibility Trial of Traumatic Brain Injured Patients Randomized in the Prehospital Setting to Either Hypertonic Saline and Dextran Versus Normal Saline

This clinical trial will evaluate the ease of conducting a randomized trial on patients with severe head injury who are cared for by paramedics in the out of hospital setting. The trial will compare two different kinds of fluids that are commonly used to elevate blood pressure and minimize the impact of the brain injury. The two solutions are a salt solution of different concentrations. One is a normal saline solution similar to the consistency of human blood and the other is a higher concentration mixed with a sugar that helps to keep the solution in the blood stream longer. This study is conducted without patient consent at the time of the study enrolment. The study will report on whether this trial is feasible in the out of hospital setting before launching into a larger definitive trial.

Completed

Looking for future studies?

Notify Me

Key information

Age range

16 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

St Michael's Hospital, Toronto, Ontario, Canada

Loading trial locations.

About this study

The Toronto Prehospital Hypertonic Resuscitation-Head Injury and Multi Organ Dysfunction Trial (TOPHR HIT) is a randomized, placebo-controlled out of hospital trial of blunt trauma patients with head injuries. The study compares a group receiving normal saline according to a paramedic's protocol, with a treatment group receiving a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 (RescueFlow BioPhausia AB, Stockholm Sweden).

The primary objective of this study is to report feasibility in accordance with the methodology described by Lancaster and Dodds*, specifically addressing:

  • baseline survival rates for the treatment and control group to aid in the design of a definitive multicentre trial.
  • randomization compliance rate.
  • ease of protocol implementation in the out-of-hospital setting.
  • adverse rate of HSD infusion.

The secondary objectives include measuring the effect of HSD in modulating the immuno-inflammatory response to severe head injury and its effect on modulating the release of neuro-biomarkers into serum; evaluating the role of serum neuro-biomarkers in predicting patient outcome and clinical response to HSD intervention; evaluating effects of HSD on brain atrophy post-injury and neurocognitive and neuropsychological outcomes.

*Lancaster, G.A., S. Dodd, and P.R. Williamson, Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract, 2004. 10(2): p. 307-12.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 16;
  • Initial assessment of GCS 8 or less;
  • Blunt traumatic mechanism of injury.

Exclusion criteria

  • Known pregnancy;
  • Primary injury penetrating;
  • VSA prior to randomization;
  • Previous Intravenous therapy ≥ 50 ml;
  • Time interval between arrival at scene and intravenous access exceeds four hours;
  • Amputation above wrist or ankle;
  • Any burn (thermal, chemical, electrical, radiation)
  • Suspected hypothermia;
  • Asphyxia (strangulation, hanging, choking, suffocation, drowning)
  • Fall from height ≤ 1m or ≤ 5 Stairs

Treatment and study plan

hypertonic saline mixed with dextran

Drug

a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident

Other names: RescueFlow BioPhausia AB, Stockholm Sweden

normal saline

Drug

250 ccs of normal saline infused within 4 hours of the accident

Primary outcomes

  1. baseline survival rates for the treatment and control group to aid in the design of a definitive multicentre trial

    Time frame: survival at 48 hours, hospital discharge, 30 days and 4 months

  2. randomization compliance rate

    Time frame: duration of enrolment

  3. ease of protocol implementation in the out-of-hospital setting

    Time frame: duration of study

  4. adverse event rate of hypertonic saline dextran infusion

    Time frame: duration of study

Secondary outcomes

  1. neurocognitive outcomes at discharge (cerebral performance category) and at 4 months (functional independence measure, disability rating scale, Glasgow Outcome Scale and Glasgow outcome Scale Extended

    Time frame: discharge and at 4 months post incident

  2. neuropsychological outcomes including learning and memory, working memory, executive function, language function, visuospatial function, speed of processing and Beck Depression Scale. A focused attention reaction time test was added to 12 month testing.

    Time frame: at 4 and 12 months post incident

  3. magnetic resonance imaging to evaluate effects of HSD on brain atrophy post-injury

    Time frame: 4 months post incident

  4. the effect of HSD in modulating the immuno-inflammatory response to severe head injury and its effect on modulation the release of neuro-biomarkers into serum; evaluating the role of serum neuro-biomarkers in predicting patient outcome

    Time frame: samples taken within 48 hours of incident

Sponsors and collaborators

Lead sponsor

Unity Health Toronto

Other

Collaborators

  • Defence Research and Development Canada
  • Sunnybrook Health Sciences Centre

Registry information

Official study title

The Toronto Prehospital Hypertonic Resuscitation Head Injury and Multi Organ Dysfunction Trial

Acronym: TOPHR HIT

Important dates

Study start
2004
Primary completion
2006
Study completion
2008
First posted
Apr 9, 2009
Registry last updated
Apr 9, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.